Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
by
Eeles, Ros
, Kote-Jarai, Zsofia
, Pharoah, Paul D. P.
, Callender, Tom
, Morris, Steve
, Pashayan, Nora
, Emberton, Mark
in
Age
/ Aged
/ Antigens
/ Cancer research
/ Cancer screening
/ Comparative analysis
/ Computer simulation
/ Cost analysis
/ Cost-Benefit Analysis
/ Decision making
/ Early Detection of Cancer - methods
/ Economic aspects
/ England
/ Epidemiology
/ Fatalities
/ Genetic aspects
/ Health aspects
/ Health care costs
/ Health risks
/ Humans
/ Incidence
/ Life Tables
/ Male
/ Mass Screening - methods
/ Mathematical models
/ Medical economics
/ Medical research
/ Medical tests
/ Medicine and Health Sciences
/ Mental task performance
/ Middle Aged
/ Mortality
/ Parameter uncertainty
/ Population
/ Population studies
/ Prevention
/ Preventive medicine
/ Prostate cancer
/ Prostate-specific antigen
/ Prostate-Specific Antigen - analysis
/ Prostatic Neoplasms - diagnosis
/ Prostatic Neoplasms - epidemiology
/ Quality-Adjusted Life Years
/ Retirement benefits
/ Risk Assessment
/ Sensitivity analysis
/ Social Sciences
/ Software
/ Task forces
/ Thresholds
/ Tradeoffs
/ United Kingdom
2019
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
by
Eeles, Ros
, Kote-Jarai, Zsofia
, Pharoah, Paul D. P.
, Callender, Tom
, Morris, Steve
, Pashayan, Nora
, Emberton, Mark
in
Age
/ Aged
/ Antigens
/ Cancer research
/ Cancer screening
/ Comparative analysis
/ Computer simulation
/ Cost analysis
/ Cost-Benefit Analysis
/ Decision making
/ Early Detection of Cancer - methods
/ Economic aspects
/ England
/ Epidemiology
/ Fatalities
/ Genetic aspects
/ Health aspects
/ Health care costs
/ Health risks
/ Humans
/ Incidence
/ Life Tables
/ Male
/ Mass Screening - methods
/ Mathematical models
/ Medical economics
/ Medical research
/ Medical tests
/ Medicine and Health Sciences
/ Mental task performance
/ Middle Aged
/ Mortality
/ Parameter uncertainty
/ Population
/ Population studies
/ Prevention
/ Preventive medicine
/ Prostate cancer
/ Prostate-specific antigen
/ Prostate-Specific Antigen - analysis
/ Prostatic Neoplasms - diagnosis
/ Prostatic Neoplasms - epidemiology
/ Quality-Adjusted Life Years
/ Retirement benefits
/ Risk Assessment
/ Sensitivity analysis
/ Social Sciences
/ Software
/ Task forces
/ Thresholds
/ Tradeoffs
/ United Kingdom
2019
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
by
Eeles, Ros
, Kote-Jarai, Zsofia
, Pharoah, Paul D. P.
, Callender, Tom
, Morris, Steve
, Pashayan, Nora
, Emberton, Mark
in
Age
/ Aged
/ Antigens
/ Cancer research
/ Cancer screening
/ Comparative analysis
/ Computer simulation
/ Cost analysis
/ Cost-Benefit Analysis
/ Decision making
/ Early Detection of Cancer - methods
/ Economic aspects
/ England
/ Epidemiology
/ Fatalities
/ Genetic aspects
/ Health aspects
/ Health care costs
/ Health risks
/ Humans
/ Incidence
/ Life Tables
/ Male
/ Mass Screening - methods
/ Mathematical models
/ Medical economics
/ Medical research
/ Medical tests
/ Medicine and Health Sciences
/ Mental task performance
/ Middle Aged
/ Mortality
/ Parameter uncertainty
/ Population
/ Population studies
/ Prevention
/ Preventive medicine
/ Prostate cancer
/ Prostate-specific antigen
/ Prostate-Specific Antigen - analysis
/ Prostatic Neoplasms - diagnosis
/ Prostatic Neoplasms - epidemiology
/ Quality-Adjusted Life Years
/ Retirement benefits
/ Risk Assessment
/ Sensitivity analysis
/ Social Sciences
/ Software
/ Task forces
/ Thresholds
/ Tradeoffs
/ United Kingdom
2019
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
Journal Article
Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
2019
Request Book From Autostore
and Choose the Collection Method
Overview
The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69. Knowing how the potential benefits and harms of screening vary by an individual's risk of developing prostate cancer could inform decision-making about screening at both an individual and population level. This modelling study examined the benefit-harm tradeoffs and the cost-effectiveness of a risk-tailored screening programme compared to age-based and no screening.
A life-table model, projecting age-specific prostate cancer incidence and mortality, was developed of a hypothetical cohort of 4.48 million men in England aged 55 to 69 years with follow-up to age 90. Risk thresholds were based on age and polygenic profile. We compared no screening, age-based screening (quadrennial PSA testing from 55 to 69), and risk-tailored screening (men aged 55 to 69 years with a 10-year absolute risk greater than a threshold receive quadrennial PSA testing from the age they reach the risk threshold). The analysis was undertaken from the health service perspective, including direct costs borne by the health system for risk assessment, screening, diagnosis, and treatment. We used probabilistic sensitivity analyses to account for parameter uncertainty and discounted future costs and benefits at 3.5% per year. Our analysis should be considered cautiously in light of limitations related to our model's cohort-based structure and the uncertainty of input parameters in mathematical models. Compared to no screening over 35 years follow-up, age-based screening prevented the most deaths from prostate cancer (39,272, 95% uncertainty interval [UI]: 16,792-59,685) at the expense of 94,831 (95% UI: 84,827-105,630) overdiagnosed cancers. Age-based screening was the least cost-effective strategy studied. The greatest number of quality-adjusted life-years (QALYs) was generated by risk-based screening at a 10-year absolute risk threshold of 4%. At this threshold, risk-based screening led to one-third fewer overdiagnosed cancers (64,384, 95% UI: 57,382-72,050) but averted 6.3% fewer (9,695, 95% UI: 2,853-15,851) deaths from prostate cancer by comparison with age-based screening. Relative to no screening, risk-based screening at a 4% 10-year absolute risk threshold was cost-effective in 48.4% and 57.4% of the simulations at willingness-to-pay thresholds of GBP£20,000 (US$26,000) and £30,000 ($39,386) per QALY, respectively. The cost-effectiveness of risk-tailored screening improved as the threshold rose.
Based on the results of this modelling study, offering screening to men at higher risk could potentially reduce overdiagnosis and improve the benefit-harm tradeoff and the cost-effectiveness of a prostate cancer screening program. The optimal threshold will depend on societal judgements of the appropriate balance of benefits-harms and cost-effectiveness.
Publisher
Public Library of Science,Public Library of Science (PLoS)
MBRLCatalogueRelatedBooks
Related Items
Related Items
We currently cannot retrieve any items related to this title. Kindly check back at a later time.
This website uses cookies to ensure you get the best experience on our website.